Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials

Overview

Journal Chin Med J (Engl)

Specialty General Medicine

Date 2016 Apr 12

PMID 27064045

Citations 4

Authors

Lei Xu

Xiao-Wei Hu

Shu-Hua Zhang

Ji-Min Li

Hui Zhu

Ke Xu

Jun Chen

Chun-Jian Li

Affiliations

Soon will be listed here.

Abstract

Background: Clopidogrel low response (CLR) is an independent risk factor of adverse outcomes in patients undergoing percutaneous coronary intervention (PCI), and intensified antiplatelet treatments (IAT) guided by platelet function assays might overcome laboratory CLR. However, whether IAT improves clinical outcomes is controversial.

Methods: Relevant trials were identified in PubMed, the Cochrane Library, and the Chinese Medical Journal Network databases from their establishment to September 9, 2014. Trials were screened using predefined inclusion criteria. Conventional meta-analysis and cumulative meta-analysis were performed using the Review Manager 5.0 and STATA 12.0 software programs.

Results: Thirteen randomized controlled trials involving 5111 patients with CLR were recruited. During a follow-up period of 1-12 months, the incidences of cardiovascular (CV) death, nonfatal myocardial infarction (MI), and stent thrombosis were significantly lower in the IAT arm than in the conventional antiplatelet treatment arm (relative risk [RR] = 0.45, 95% confidence interval [CI]: 0.36-0.57, P < 0.000,01), whereas bleeding was similar between the two arms (RR = 1.05, 95% CI: 0.86-1.27, P = 0.65).

Conclusions: IAT guided by platelet function assays reduces the risk of CV death, nonfatal MI, and stent thrombosis (ST) without an increased risk of bleeding in patients undergoing PCI and with CLR.

Citing Articles

High On-Treatment Platelet Reactivity in Patients Undergoing Complex Percutaneous Coronary Interventions.

Urban L, Ingrid S, Zolkova J, Jan S, Bolek T, Samos M Clin Appl Thromb Hemost. 2023; 29:10760296231199089.

PMID: 37697705 PMC: 10498693. DOI: 10.1177/10760296231199089.

A brief review on resistance to P2Y receptor antagonism in coronary artery disease.

Warlo E, Arnesen H, Seljeflot I Thromb J. 2019; 17:11.

PMID: 31198410 PMC: 6558673. DOI: 10.1186/s12959-019-0197-5.

Comparison of treatment outcomes of ticagrelor and clopidogrel among patients undergoing percutaneous coronary intervention: A meta-analysis.

Yang J, Zeng P, Cai W J Huazhong Univ Sci Technolog Med Sci. 2017; 37(5):675-680.

PMID: 29058279 DOI: 10.1007/s11596-017-1788-7.

Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.

Zhou Y, Wang Y, Wu Y, Huang C, Yan H, Zhu W BMC Cardiovasc Disord. 2017; 17(1):157.

PMID: 28619104 PMC: 5472866. DOI: 10.1186/s12872-017-0582-6.

References

Moher D, Pham B, Jones A, Cook D, Jadad A, Moher M . Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998; 352(9128):609-13. DOI: 10.1016/S0140-6736(98)01085-X. View

Siller-Matula J, Jilma B . Why have studies of tailored anti-platelet therapy failed so far?. Thromb Haemost. 2013; 110(4):628-31. DOI: 10.1160/TH13-03-0250. View

Sibbing D, Steinhubl S, Schulz S, Schomig A, Kastrati A . Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol. 2010; 56(4):317-8. DOI: 10.1016/j.jacc.2010.03.048. View

Wang X, Zhang D, Zhuang S, Lai Y . Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol. 2011; 34(5):332-8. PMC: 6652726. DOI: 10.1002/clc.20884. View

Price M, Angiolillo D, Teirstein P, Lillie E, Manoukian S, Berger P . Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011; 124(10):1132-7. DOI: 10.1161/CIRCULATIONAHA.111.029165. View

Hazarbasanov D, Velchev V, Finkov B, Postadjian A, Kostov E, Rifai N . Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis. 2012; 34(1):85-90. DOI: 10.1007/s11239-012-0684-z. View

Aradi D, Rideg O, Vorobcsuk A, Magyarlaki T, Magyari B, Konyi A . Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. Eur J Clin Invest. 2011; 42(4):384-92. DOI: 10.1111/j.1365-2362.2011.02594.x. View

Cuisset T, Frere C, Quilici J, Morange P, Mouret J, Bali L . Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv. 2009; 1(6):649-53. DOI: 10.1016/j.jcin.2008.08.018. View

Tang F, Lin L, Hua N, Lu H, Qi Z, Tang X . Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention. Chin Med J (Engl). 2012; 125(4):631-8. View

10.

Braunwald E, Antman E, Beasley J, Califf R, Cheitlin M, Hochman J . ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice.... J Am Coll Cardiol. 2002; 40(7):1366-74. DOI: 10.1016/s0735-1097(02)02336-7. View

11.

Barragan P, Bouvier J, Roquebert P, Macaluso G, Commeau P, Comet B . Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003; 59(3):295-302. DOI: 10.1002/ccd.10497. View

12.

Trenk D, Stone G, Gawaz M, Kastrati A, Angiolillo D, Muller U . A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet.... J Am Coll Cardiol. 2012; 59(24):2159-64. DOI: 10.1016/j.jacc.2012.02.026. View

13.

Siller-Matula J, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G . Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol. 2012; 167(5):2018-23. DOI: 10.1016/j.ijcard.2012.05.040. View

14.

Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T . Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J. 2010; 160(3):543-51. DOI: 10.1016/j.ahj.2010.06.004. View

15.

Collet J, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C . Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012; 367(22):2100-9. DOI: 10.1056/NEJMoa1209979. View

16.

Guan S, Han Y, Li Y, Guo L, Yang B, Wang S . [Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation]. Zhonghua Xin Xue Guan Bing Za Zhi. 2012; 40(1):25-9. View

17.

Price M, Berger P, Teirstein P, Tanguay J, Angiolillo D, Spriggs D . Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011; 305(11):1097-105. DOI: 10.1001/jama.2011.290. View

18.

Bonello L, Tantry U, Marcucci R, Blindt R, Angiolillo D, Becker R . Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010; 56(12):919-33. DOI: 10.1016/j.jacc.2010.04.047. View

19.

Samardzic J, Krpan M, Skoric B, Pasalic M, Petricevic M, Milicic D . Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity. J Thromb Thrombolysis. 2014; 38(4):459-69. DOI: 10.1007/s11239-014-1087-0. View

20.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp C . A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. Int J Cardiol. 2011; 160(2):109-13. DOI: 10.1016/j.ijcard.2011.04.001. View